Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Breast Cancer Res Treat. 2015 Oct 22;154(2):275–286. doi: 10.1007/s10549-015-3612-z

Table 1.

Patient and tumor characteristics of the HR+/HER2- analysis population, overall and according to cohort.

Characteristic Cohort Overall HR+/HER2-Population
No chemo SOFT No chemo TEXT Chemo TEXT Prior chemo SOFT
N % N % N % N % N %
N Patients 1135 100.0 844 100.0 1073 100.0 1063 100.0 4115 100.0
Age at randomization 15 1.3 35 4.1 116 10.8 190 17.9 356 8.7
 <35
 35-39 86 7.6 89 10.5 188 17.5 307 28.9 670 16.3
 40-44 302 26.6 296 35.1 364 33.9 345 32.5 1307 31.8
 45-49 515 45.4 322 38.2 341 31.8 183 17.2 1361 33.1
 50+ 217 19.1 102 12.1 64 6.0 38 3.6 421 10.2
No. nodes positive 1039 91.5 661 78.3 353 32.9 444 41.8 2497 60.7
 N0
 N 1-3 95 8.4 181 21.4 451 42.0 429 40.4 1156 28.1
 N 4+ 1 0.1 2 0.2 269 25.1 190 17.9 462 11.2
Tumor size (path.; cm)
 ≤2 cm 975 85.9 670 79.4 487 45.4 532 50.0 2664 64.7
 >2 cm 154 13.6 174 20.6 576 53.7 499 46.9 1403 34.1
 Unknown 6 0.5 - - 10 0.9 32 3.0 48 1.2
Centrally-assessed
Tumor grade
 1 420 37.0 210 24.9 143 13.3 156 14.7 929 22.6
 2 602 53.0 496 58.8 603 56.2 619 58.2 2320 56.4
 3 108 9.5 135 16.0 320 29.8 282 26.5 845 20.5
 Not determined 5 0.4 3 0.4 7 0.7 6 0.6 21 0.5
Vessel invasion (lymphatics and/or blood vessels)
 No 1013 89.3 682 80.8 695 64.8 792 74.5 3182 77.3
 Yes 120 10.6 161 19.1 374 34.9 268 25.2 923 22.4
 Not determined 2 0.2 1 0.1 4 0.4 3 0.3 10 0.2
Estrogen receptor (ER)
 <10% 1 0.1 - - 6 0.6 11 1.0 18 0.4
 10-49% 13 1.1 12 1.4 35 3.3 22 2.1 82 2.0
 ≥50% 1103 97.2 826 97.9 1020 95.1 1011 95.1 3960 96.2
 Not determined 18 1.6 6 0.7 12 1.1 19 1.8 55 1.3
 Median and IQR 95 90-99 95 90-99 90 85-99 95 90-99 95 90-99
Progesterone receptor (PgR)
 <10% 28 2.5 36 4.3 92 8.6 131 12.3 287 7.0
 10-19% 13 1.1 10 1.2 36 3.4 47 4.4 106 2.6
 20-49% 42 3.7 50 5.9 110 10.3 105 9.9 307 7.5
 ≥50% 1034 91.1 735 87.1 822 76.6 761 71.6 3352 81.5
 Not determined 18 1.6 13 1.5 13 1.2 19 1.8 63 1.5
 Median and IQR 95 90-99 90 80-99 90 60-95 90 40-95 90 70-99
Ki-67 expression
 <14% 505 44.5 269 31.9 198 18.5 247 23.2 1219 29.6
 14-19% 324 28.5 261 30.9 293 27.3 302 28.4 1180 28.7
 20-25% 152 13.4 135 16.0 234 21.8 216 20.3 737 17.9
 >26% 101 8.9 135 16.0 310 28.9 236 22.2 782 19.0
 Not determined 53 4.7 44 5.2 38 3.5 62 5.8 197 4.8
 Median and IQR 14 9-19 16 11-22 20 15-27 18 14-25 18 12-24
Luminal A/B-likea
 A-like 796 70.1 507 60.1 448 41.8 480 45.2 2231 54.2
 B-like 279 24.6 291 34.5 585 54.5 519 48.8 1674 40.7
 Not determined 60 5.3 46 5.5 40 3.7 64 6.0 210 5.1

Abbreviations: IQR=interquartile range; SOFT=Suppression of Ovarian Function Trial; TEXT=Tamoxifen and Exemestane Trial.

a: Defined according to 2013 St. Gallen Consensus: in HR+/HER2-negative disease, Luminal A-like is PgR≥20% and Ki-67<20%; B-like is either PgR<20% or Ki-67≥20%.